Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Quantum Group Investment Management, also known as Quantum Innovation Fund Management Pty Ltd, is an investment management firm based in Chermside, Queensland, Australia. Founded to address the funding gap in early to mid-stage medical technology, Quantum focuses on providing capital solutions for the development of high-performance medical technologies that enhance patient care. The firm operates as a registered Venture Capital Limited Partnership with Innovation and Sciences Australia, indicating a formal fund structure.
Currently, Quantum manages a portfolio of over 50 companies and has reviewed more than 100 proprietary technologies. The firm emphasizes active management of its investments, offering commercial expertise and support services to aid in the development and market implementation of its portfolio companies. Quantum's team consists of experienced professionals from various sectors, including healthcare and finance, which enhances its ability to support startups effectively.
Quantum Group Investment Management is dedicated to addressing large unmet clinical needs in the healthcare sector, particularly in cardiovascular, respiratory, and chronic disease markets. The firm’s commitment to enhancing patient outcomes through innovative medical technologies positions it as a key player in the Australian investment landscape.
Quantum Group Investment Management specializes in investing in early to mid-stage medical technologies, particularly within the cardiovascular, respiratory, and chronic disease sectors. The firm targets technologies that demonstrate significant innovation and have a total addressable market exceeding $500 million. Investments typically range from $15 million to $20 million per company, allowing Quantum to provide substantial support to its portfolio companies.
The firm emphasizes the importance of clear pathways to regulatory approval for the technologies it invests in. Quantum seeks out innovations that not only address pressing clinical needs but also have protectable intellectual property and a realistic commercialization strategy. This focus on regulatory pathways ensures that the technologies can be effectively brought to market, ultimately improving patient care.
Quantum's investment strategy is rooted in its belief that addressing large unmet clinical needs can lead to significant advancements in healthcare. The firm actively manages its investments, providing commercial expertise and access to a network of medical and capital-markets advisors to help portfolio companies navigate the complexities of the medical technology landscape.
Quantum Group Investment Management has a diverse portfolio of over 50 companies, focusing on innovative medical technologies. While specific portfolio companies are not disclosed, the firm has reviewed more than 100 proprietary technologies, indicating a robust pipeline of potential investments. The firm actively manages its portfolio, providing commercial expertise and support services to aid in the development and market implementation of its technologies.
Quantum's portfolio includes companies that specialize in various aspects of medical technology, particularly in the cardiovascular, respiratory, and chronic disease sectors. The firm’s approach to investment emphasizes technologies that have clear regulatory pathways and significant market potential, ensuring that its portfolio companies are well-positioned for success.
Although specific names of portfolio companies are not available, Quantum's focus on early to mid-stage investments in medical technologies highlights its commitment to supporting innovations that can enhance patient care and address critical healthcare challenges.
Mark Phillips - CEO & COO. Mark has over 30 years of fund management experience and a strong background in capital markets. He plays a crucial role in overseeing the firm's operations and investment strategies.
John Corbett - Chair - Investment Committee. John brings more than 30 years of experience in business, advisory, and banking, having held senior roles at ANZ and Suncorp. His expertise in governance and commercial leadership is vital for the firm's investment decisions.
Sonia Barber - Chief Legal Officer. Sonia is an international projects and investment lawyer with experience in projects and investments connected to the Middle East. Her legal expertise supports the firm's compliance and investment strategies.
Professor John Fraser - Medical Advisory Panel Member. John is an intensivist at The Prince Charles Hospital and the founder/head of the Critical Care Research Group, providing valuable insights into medical technologies.
Professor Daniel Brodie - Medical Advisory Panel Member. Daniel is a pulmonary and critical-care physician with training from Johns Hopkins and Columbia, contributing his medical expertise to the firm's investment evaluations.
Professor Daniel McAuley - Medical Advisory Panel Member. Daniel is a professor of intensive-care medicine and consultant connected with Queen's University Belfast, offering critical insights into the healthcare landscape.
To pitch Quantum Group Investment Management, founders should submit their proposals through the firm's website. It is essential to include a comprehensive deck that outlines the clinical need, technology differentiation, intellectual property status, market size, regulatory path, and potential for patient adoption.
Quantum prefers pitches that are clear and concise, allowing their medical advisory and investment team to assess the opportunity effectively. While there is no specific application form mentioned, a well-structured presentation is crucial. Founders should expect a response within a reasonable timeframe, although specific timelines are not disclosed.
As of April 2023, Quantum Group Investment Management has been actively reviewing and managing a robust pipeline of medical technologies, with over 100 proprietary technologies reviewed and more than 50 currently in the pipeline. The firm continues to focus on early to mid-stage investments in medical technologies, particularly in the cardiovascular, respiratory, and chronic disease sectors.
Quantum has not publicly disclosed specific recent investments or exits, but its ongoing commitment to addressing the funding gap in medical technology remains evident through its active management and support of portfolio companies.
What are Quantum Group's investment criteria?
Quantum Group focuses on early to mid-stage medical technologies, particularly in the cardiovascular, respiratory, and chronic disease sectors. They look for innovations with a total addressable market exceeding $500 million and clear pathways to regulatory approval.
How can I pitch to Quantum Group?
Founders can pitch their companies through the Quantum Group website. It is recommended to include details about the clinical need, technology differentiation, intellectual property status, market size, regulatory path, and potential for patient adoption in the pitch.
What is the typical check size Quantum Group invests?
Quantum typically invests between $15 million and $20 million per company, providing substantial capital to support the development of innovative medical technologies.
What kind of support does Quantum Group provide to portfolio companies?
Quantum offers active post-investment support, including commercial expertise and access to a network of medical and capital-markets advisors. This hands-on approach helps portfolio companies navigate the complexities of bringing their technologies to market.
What geographic areas does Quantum Group focus on?
Quantum Group is based in Chermside, Queensland, Australia, and primarily focuses on investments within Oceania, particularly Australia.
What makes Quantum Group different from other investors?
Quantum Group specializes in medical technologies with a strong emphasis on regulatory pathways and clinical needs. Their active management style and focus on healthcare innovation set them apart from more generalist investors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.